NCT06190483View on ClinicalTrials.gov

Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

March 24, 2023

Study Completion Date

March 24, 2023

Conditions
Prodromal Schizophrenia
Interventions
DRUG

Diazepam 5 Mg Oral Tablet

Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

DRUG

Ascorbic Acid 50 Mg Oral Tablet

Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

Trial Locations (1)

SE8 5AF

Institute of Psychiatry, Psychology and Neuroscience, London

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

The Royal Society

UNKNOWN

lead

King's College London

OTHER

NCT06190483 - Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk | Biotech Hunter | Biotech Hunter